ASCO 2025 Highlights

The Department of Veterans Affairs has been able to “dramatically increase” clinical trial opportunities and participation over the past 2 years, thanks in part to a joint initiative from the Prostate Cancer Foundation and Veterans Affairs,... Read More ›

Access to treatment and survival outcomes among US veterans with stage I non–small cell lung cancer may vary depending on demographic and sociological patterns,... Read More ›

The phase 3 DeLLphi-304 study evaluated tarlatamab, a bispecific T-cell engager immunotherapy, versus chemotherapy in patients with small cell lung cancer that progressed on or after platinum-based chemotherapy. Read More ›

The phase 3 IMforte study evaluated the efficacy and safety of first-line maintenance treatment with lurbinectedin combined with atezolizumab versus atezolizumab alone in patients with extensive-stage small cell lung cancer. Read More ›